Jump to content

Technetium (99mTc) tilmanocept

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Whywhenwhohow (talk | contribs) at 03:55, 29 October 2020 (update infobox; add link and portal). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Technetium (99mTc) tilmanocept
Clinical data
Trade namesLymphoseek
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Pregnancy
category
  • AU: C
Routes of
administration		Intradermal, subcutaneous, intratumor
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life1.75 to 3.05 hours at injection site
Identifiers
  • Dextran 3-[(2-aminoethyl)thio]propyl 17-carboxy-10,13,16-tris(carboxymethyl)-8-oxo-4-thia-7,10,13,16-tetraazaheptadec-1-yl 3-[[2-[[1-imino-2-(D-mannopyranosylthio)ethyl]amino]ethyl]thio]propyl ether technetium-99m complexes
KEGG
Chemical and physical data
Formula(C6H10O5)n(C19H28N4O9S99mTc)3–8(C13H24N2O5S2)12–20(C5H11NS)0–17
Molar mass15,281–23,454 g/mol[4]

Technetium (99mTc) tilmanocept, trade name Lymphoseek, is a radiopharmaceutical diagnostic imaging agent used to locate lymph nodes which may be draining from tumors, and assist doctors in locating lymph nodes for removal during surgery.[6]

The most common side effects identified in clinical trials was pain or irritation at the injection site.[7]

It was approved by the U.S. Food and Drug Administration (FDA) in March 2013, for the imaging of lymph nodes.[4][7]

References

  1. ^ "Lymphoseek kit for the preparation of technetium [99m Tc] tilmanocept injection vial". Therapeutic Goods Administration (TGA). Retrieved 28 October 2020.
  2. ^ "Summary for ARTG Entry: 296337 Lymphoseek kit for the preparation of technetium [99m Tc] tilmanocept injection vial" (PDF). Therapeutic Goods Administration (TGA). Retrieved 28 October 2020.
  3. ^ "Lymphoseek 50 micrograms kit for radiopharmaceutical preparation - Summary of Product Characteristics (SmPC)". (emc). 18 May 2020. Retrieved 28 October 2020.
  4. ^ a b c "Kit for the preparation of Lymphoseek (technetium tc 99m tilmanocept)- tilmanocept kit". DailyMed. 8 July 2019. Retrieved 28 October 2020.
  5. ^ "Lymphoseek EPAR". European Medicines Agency (EMA). Retrieved 28 October 2020.
  6. ^ Marcinow AM, Hall N, Byrum E, Teknos TN, Old MO, Agrawal A (September 2013). "Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: initial institutional report in an ongoing phase 3 study". JAMA Otolaryngology–Head & Neck Surgery. 139 (9): 895–902. doi:10.1001/jamaoto.2013.4239. PMC 4301415. PMID 24051744.
  7. ^ a b "FDA approves Lymphoseek to help locate lymph nodes in patients with certain cancers" (Press release). U.S. Food and Drug Administration (FDA). 13 March 2013. Archived from the original on 30 March 2014.

External links

Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This medical diagnostic article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Technetium_(99mTc)_tilmanocept&oldid=985988463"